ReviewTargeted oncology2009
Targeting insulin-like growth factor type 1 receptor in cancer therapy.
Review in Targeted oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- Trial
- Molecular Targets in Alveolar Rhabdomyosarcoma: A Narrative Review of Progress and Pitfalls.International journal of molecular sciences · 2025Review
- Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports.Biomolecules · 2021Review
- Prognostic and therapeutic implications of NHERF1 expression and regulation in colorectal cancer.Journal of surgical oncology · 2020Article
- IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.Journal of the National Cancer Institute · 2016Article
- How interacting pathways are regulated by miRNAs in breast cancer subtypes.BMC bioinformatics · 2016Article
- Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.Cancer chemotherapy and pharmacology · 2015Article
- Simulation predicts IGFBP2-HIF1α interaction drives glioblastoma growth.PLoS computational biology · 2015Article
- Engineered ubiquitin ligase PTB-U-box targets insulin/insulin-like growth factor receptor for degradation and coordinately inhibits cancer malignancy.Oncotarget · 2014Article
- Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.BMC cancer · 2014Article
- Ezrin expression and cell survival regulation in colorectal cancer.Cellular signalling · 2014Article
- In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer.Oncology reports · 2014Article
- Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.Cancer research · 2013Article
- Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance.Cancers · 2011Article
- Biochemical and structural characterization of lysophosphatidic Acid binding by a humanized monoclonal antibody.Journal of molecular biology · 2011Article
- Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.Molecular cancer therapeutics · 2011Article
- Luminal-B breast cancer and novel therapeutic targets.Breast cancer research : BCR · 2011Review
- Targeting mTOR in cancer: renal cell is just a beginning.Targeted oncology · 2010Review
- Allosteric IGF-1R Inhibitors.ACS medicinal chemistry letters · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is believed that the insulin-like growth factor receptor type 1 (IGF-1R) signaling pathway plays a pivotal role in cancer growth, progression, and resistance to anticancer therapies. Strategies are being developed to block IGF-1R as an anticancer treatment. We reviewed several potential strategies for disrupting the IGF axis. We also reviewed the effects of two drugs that target the IGF-1R: monoclonal antibodies and tyrosine kinase inhibitors. Preliminary results of studies involving these agents provided a foundation for ongoing clinical trials, whose results in the near future will help us understand how to incorporate anti IGF-1R strategies into the current anticancer armamentarium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.